(Q46816802)

English

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

scientific article published on 22 November 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

0 references

1 reference

based on heuristic

inferred from title

Gunnar Folprecht

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

author name string

P Schöffski

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

T Seufferlein

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

A Nolting

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

P Pollert

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

C-H Köhne

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

publication date

22 November 2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

17

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

450-456

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

The role of new agents in the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ084

21 January 2018

Identifiers

10.1093/ANNONC/MDJ084

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16303861

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46816802&oldid=2133388708"